About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>golimumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Simponi®</td>
</tr>
</tbody>
</table>
| Dosage Form(s) | 50 mg/0.5 ml Auto-injector and Pre-filled Syringe  
100 mg/0.1 ml Auto-injector and Pre-filled Syringe |
| Manufacturer | Janssen Inc. |

Submission Type

New Indication

Use Reviewed

Ulcercative Colitis (UC)

Common Drug Review (CDR)

Yes, CDR recommended: **Do not list at the submitted price.**
Visit the CDR website for more details: [www.cadth.ca/node/88649](http://www.cadth.ca/node/88649).

Drug Benefit Council (DBC)

DBC met on April 14, 2014. DBC considered various inputs including: clinical and pharmacoeconomic evidence review material prepared by CDR and the recommendation from the Canadian Drug Expert Committee (CDEC), input from a specialist, and one patient, one caregiver and three Patient Groups, comments from the manufacturer and budget impact assessment.

Drug Coverage Decision

Non-Benefit

Date

May 31, 2016

Reason(s)

Drug coverage decision is consistent with the DBC recommendation.
- Golimumab SC did demonstrate advantages over placebo with respect to efficacy, but was not compared to any other comparator.
- There was no difference in the clinical trials between placebo and golimumab with regard to incidence of adverse events and serious adverse events.
- Based on economic considerations and the submitted product price, the DBC was uncertain of the value prospect of golimumab in ulcerative colitis due to substantial weaknesses in the economic evidence.
- BC participated in negotiations with the manufacturer for golimumab SC for the treatment of UC through the pan-Canadian Pharmaceutical Alliance (pCPA), but BC opted out of the negotiations as the acceptable value was not reached through the negotiations and golimumab does not provide clinical advantage over available options.

Other Information

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. Drug Review Process and PharmaCare program for more information.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.